157 related articles for article (PubMed ID: 6286122)
1. Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
[No Abstract] [Full Text] [Related]
2. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
3. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
4. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
[No Abstract] [Full Text] [Related]
6. Phase I study of 6-diazo-5-oxo-L-norleucine (DON).
Sklaroff RB; Casper ES; Magill GB; Young CW
Cancer Treat Rep; 1980; 64(12):1247-51. PubMed ID: 7471114
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.
Rubin J; Sorensen S; Schutt AJ; van Hazel GA; O'Connell MJ; Moertel CG
Am J Clin Oncol; 1983 Jun; 6(3):325-6. PubMed ID: 6846250
[No Abstract] [Full Text] [Related]
8. Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Joss RA; Obrecht JP; Alberto P; Siegenthaler P; VanHelvoirt A; Cavalli F
Cancer Treat Rep; 1984 Mar; 68(3):563-4. PubMed ID: 6322990
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
Haas CD; Baker L; Thigpen T
Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of patients with lung cancer with a combination of nitrosomethylurea and cyclophosphane].
Perevodchikova NI; Korman NP; Bychkov MB
Vopr Onkol; 1975; 21(8):21-5. PubMed ID: 170742
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
Dhingra HM; Umsawasdi T; Chiuten DF; Murphy WK; Holoye PY; Spitzer G; Valdivieso M
Cancer Treat Rep; 1986 May; 70(5):673-4. PubMed ID: 3708617
[No Abstract] [Full Text] [Related]
12. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of AMSA in patients with metastatic lung cancer.
Nichols WC; Eagan RT; Frytak S; Ingle JN; Creagan ET; Kvols LK
Cancer Treat Rep; 1980; 64(12):1383-5. PubMed ID: 6894104
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of AMSA in lung cancer.
Samson MK; Fraile RJ; Baker LH; Cummings G; Talley RW
Cancer Treat Rep; 1981; 65(7-8):655-8. PubMed ID: 6265083
[TBL] [Abstract][Full Text] [Related]
15. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Shibuya M; Shimabukuro Z
Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of triazinate in patients with metastatic lung cancer.
Creagan ET; Eagan RT; Fleming TR; Frytak S; Ingle JN; Kvols LK; Nichols WC
Cancer Treat Rep; 1980; 64(10-11):1057-9. PubMed ID: 6257389
[No Abstract] [Full Text] [Related]
17. [Polychemotherapy of small-cell bronchopulmonary cancer. The advantages of adding the selective cytostatic Riaval].
Păunescu E; Dănălache-Dumitrescu M; Oprişiu G; Smărăndache M; Stoinescu M; Vasile DI; Zaharescu C; Burnea D; Claiciu I; Ghinescu V
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1986; 35(3):233-42. PubMed ID: 3027860
[No Abstract] [Full Text] [Related]
18. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
Cancer Treat Rep; 1981; 65(11-12):1099-1101. PubMed ID: 6271397
[No Abstract] [Full Text] [Related]
19. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of anaxirone in advanced non-small cell lung cancer.
Fiebig HH; Henss H; Arnold H; von Bültzingslöwen F; Klee M; Queisser W; Peukert M
Cancer Treat Rep; 1987 May; 71(5):539-40. PubMed ID: 3567979
[No Abstract] [Full Text] [Related]
[Next] [New Search]
